5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans : A Substudy of the EnACT Trial Testing Oral Amphotericin.

Thomas C McHaleAndrew AkampuriraElliot S GerlachAtukunda MucunguziMelanie R NicolDarlisha A WilliamsKirsten NielsenTihana BicanicAnn FiebergBiyue DaiDavid B MeyaDavid R Boulwarenull null

Published in: Open forum infectious diseases (2023)

There is no evidence of baseline resistance to 5FC or incident resistance during combination therapy with oral or IV amphotericin B in Uganda. Oral amphotericin B can safely be used in combination with 5FC.

Keyphrases

combination therapy
cardiovascular disease
clinical trial
candida albicans
type diabetes
phase iii